Does Your Italian Affiliate Know About Every Clinical Study Paying Your HCPs? It Should.
Author
Noemi is a Global Solutions Delivery Manager at Vector Health Compliance, where she supports client delivery across global transparency projects. Her work focuses on data accuracy, remediation, and country-specific reporting requirements, with a particular focus on Italy. She plays a key role in coordinating client needs with internal teams to ensure timely and compliant reporting outcomes.
Vector Health Compliance
Your Leading Partner in Global Sunshine Compliance
Cerchi supporto per la compliance al Sunshine Act?
Hai domande pratiche?
Dai un’occhiata alla nostra sezione Domande Frequenti per risposte chiare su scadenze, obblighi e strategie.
The general manager of an Italian medical device affiliate can tell you the name of every key account in the country, the quarterly revenue figures, and the headcount in their sales team. Ask them which Italian HCPs are currently participating as investigators in a corporate-sponsored clinical study — and the room goes quiet.
This isn’t negligence. It’s how multinational life sciences organizations are structured. Clinical studies are among the largest sources of transfers of value to healthcare professionals, yet they are frequently managed by global or regional teams rather than local affiliates. Study protocols are developed by global medical affairs, contracts are negotiated centrally, and payments may be processed by a foreign legal entity or through a contract research organization (CRO). As a result, local teams may have little visibility into activities involving HCPs in their own market.
As companies prepare for the Italian Sunshine Act, this lack of visibility can become an operational challenge.
While the reporting obligation generally rests with the producer company responsible for the transfer of value and, where applicable, its representative in Italy, accurate reporting still depends on complete, timely information flowing between global and local functions. If data remains siloed, the reporting entity may struggle to produce a complete and accurate disclosure.
Visibility Matters More Than Ever
One of the biggest misconceptions is that payments managed outside Italy automatically become someone else’s problem. In reality, multinational organizations need clear governance over who is responsible for reporting, who collects the required data, and how information moves between global headquarters, regional functions, and local operations.
Consider a French corporate entity sponsoring a post-market clinical follow-up study involving Italian investigators. The contracts, payments, and study management may all sit outside Italy. Even so, the producer company responsible for reporting must ensure it has complete information about the transfers of value made to Italian HCPs. Achieving that often requires coordination between corporate medical affairs, finance, legal, clinical operations, and the teams supporting compliance in Italy.
The challenge, therefore, is not simply identifying who files the report. It is ensuring that the reporting entity has reliable access to all relevant payment data before reporting deadlines arrive.
What Makes Clinical Studies Particularly Complex
Clinical study payments present challenges that go well beyond ordinary consulting engagements.
Many studies span multiple years, meaning contracted amounts rarely match the payments made during a single reporting period. Investigators may receive milestone payments for site initiation, patient enrolment, interim monitoring, and study completion, with each payment potentially falling into different reporting windows.
Clinical studies are also commonly administered through CROs, adding another layer between the manufacturer and the investigator. While a CRO may execute payments or manage operational activities, companies should establish clear contractual arrangements defining what information will be shared, when it will be shared, and who remains responsible for meeting transparency reporting obligations.
Without these governance processes, organizations risk incomplete datasets, inconsistent reporting records, and unnecessary compliance challenges.
Building the Information Bridge
The solution begins with visibility.
Organizations should maintain an inventory of all active and recently completed clinical studies involving Italian HCPs, regardless of which corporate entity manages the research. This creates a single source of truth for transparency reporting teams and helps prevent studies from being overlooked.
From there, companies should establish formal information-sharing procedures between global medical affairs, clinical operations, finance, legal, and compliance teams. Whenever a payment is made to an Italian HCP under a clinical study agreement, key information, including the payment amount, recipient, payment date, study identifier, and reporting entity, should be captured and shared through a standardized process.
For organizations managing multiple global studies, these processes should be implemented well before reporting periods begin. Building governance frameworks, clarifying responsibilities, and aligning internal stakeholders is far easier months in advance than during the final weeks before a filing deadline.
Conclusion
Corporate-managed clinical studies remain one of the biggest visibility challenges in Italian Sunshine Act compliance, not because responsibility is unclear, but because the information needed for accurate reporting is often dispersed across multiple teams, systems, and legal entities.
Organizations that establish strong governance, define reporting responsibilities early, and create reliable information-sharing processes will be far better positioned to deliver complete and accurate disclosures when reporting obligations arise.
Preparing for Italian Sunshine Act reporting requires more than understanding the legislation, it requires confidence that your data is complete, accurate, and accessible across your organization.
Check out our resources and articles to understand what Italian Sunshine reporting actually means for your organization.
The general manager of an Italian medical device affiliate can tell you the name of every key account in the country, the quarterly revenue figures, and the headcount in their sales team. Ask them which Italian HCPs are currently participating as investigators in a corporate-sponsored clinical study — and the room goes quiet.
This isn’t negligence. It’s how multinational life sciences organizations are structured. Clinical studies are among the largest sources of transfers of value to healthcare professionals, yet they are frequently managed by global or regional teams rather than local affiliates. Study protocols are developed by global medical affairs, contracts are negotiated centrally, and payments may be processed by a foreign legal entity or through a contract research organization (CRO). As a result, local teams may have little visibility into activities involving HCPs in their own market.
As companies prepare for the Italian Sunshine Act, this lack of visibility can become an operational challenge.
While the reporting obligation generally rests with the producer company responsible for the transfer of value and, where applicable, its representative in Italy, accurate reporting still depends on complete, timely information flowing between global and local functions. If data remains siloed, the reporting entity may struggle to produce a complete and accurate disclosure.
Visibility Matters More Than Ever
One of the biggest misconceptions is that payments managed outside Italy automatically become someone else’s problem. In reality, multinational organizations need clear governance over who is responsible for reporting, who collects the required data, and how information moves between global headquarters, regional functions, and local operations.
Consider a French corporate entity sponsoring a post-market clinical follow-up study involving Italian investigators. The contracts, payments, and study management may all sit outside Italy. Even so, the producer company responsible for reporting must ensure it has complete information about the transfers of value made to Italian HCPs. Achieving that often requires coordination between corporate medical affairs, finance, legal, clinical operations, and the teams supporting compliance in Italy.
The challenge, therefore, is not simply identifying who files the report. It is ensuring that the reporting entity has reliable access to all relevant payment data before reporting deadlines arrive.
What Makes Clinical Studies Particularly Complex
Clinical study payments present challenges that go well beyond ordinary consulting engagements.
Many studies span multiple years, meaning contracted amounts rarely match the payments made during a single reporting period. Investigators may receive milestone payments for site initiation, patient enrolment, interim monitoring, and study completion, with each payment potentially falling into different reporting windows.
Clinical studies are also commonly administered through CROs, adding another layer between the manufacturer and the investigator. While a CRO may execute payments or manage operational activities, companies should establish clear contractual arrangements defining what information will be shared, when it will be shared, and who remains responsible for meeting transparency reporting obligations.
Without these governance processes, organizations risk incomplete datasets, inconsistent reporting records, and unnecessary compliance challenges.
Building the Information Bridge
The solution begins with visibility.
Organizations should maintain an inventory of all active and recently completed clinical studies involving Italian HCPs, regardless of which corporate entity manages the research. This creates a single source of truth for transparency reporting teams and helps prevent studies from being overlooked.
From there, companies should establish formal information-sharing procedures between global medical affairs, clinical operations, finance, legal, and compliance teams. Whenever a payment is made to an Italian HCP under a clinical study agreement, key information, including the payment amount, recipient, payment date, study identifier, and reporting entity, should be captured and shared through a standardized process.
For organizations managing multiple global studies, these processes should be implemented well before reporting periods begin. Building governance frameworks, clarifying responsibilities, and aligning internal stakeholders is far easier months in advance than during the final weeks before a filing deadline.
Conclusion
Corporate-managed clinical studies remain one of the biggest visibility challenges in Italian Sunshine Act compliance, not because responsibility is unclear, but because the information needed for accurate reporting is often dispersed across multiple teams, systems, and legal entities.
Organizations that establish strong governance, define reporting responsibilities early, and create reliable information-sharing processes will be far better positioned to deliver complete and accurate disclosures when reporting obligations arise.
Preparing for Italian Sunshine Act reporting requires more than understanding the legislation, it requires confidence that your data is complete, accurate, and accessible across your organization.
Check out our resources and articles to understand what Italian Sunshine reporting actually means for your organization.
Author
Noemi is a Global Solutions Delivery Manager at Vector Health Compliance, where she supports client delivery across global transparency projects. Her work focuses on data accuracy, remediation, and country-specific reporting requirements, with a particular focus on Italy. She plays a key role in coordinating client needs with internal teams to ensure timely and compliant reporting outcomes.
Vector Health Compliance
Your Leading Partner in Global Sunshine Compliance
Recent Blogs
-
Il punto cieco degli studi clinici: quando Corporate gestisce il budget ma la filiale locale ne risponde
-
Gli orologi nascosti: perché accordi e pagamenti possono ricadere in periodi diversi ai fini della rendicontazione Sunshine in Italia
-
Perché il transparency reporting richiede una governance interfunzionale
Cerchi supporto per la compliance al Sunshine Act?
Hai domande pratiche?
Dai un’occhiata alla nostra sezione Domande Frequenti per risposte chiare su scadenze, obblighi e strategie.